BRCA1表达与吉非替尼治疗EGFR基因突变型晚期非小细胞肺癌疗效.DOC

基金项目：广东省科技厅科技计划项目（编号：20120318077）、吴阶平医学基金项目（编号：320.6799.1115）、佛山市卫生局医学科研项目（编号：2014051） BRCA1表达与吉非替尼治疗EGFR基因突变型晚期非小细胞肺癌疗效的关系 张顺达 冯卫能 冼海兵 伍婧 唐溢聪 陈泽程 邓燕明 佛山市第一人民医院(中山大学附属佛山医院) 528000 摘要：目的：探讨BRCA1表达与吉非替尼治疗EGFR突变型晚期非小细胞肺癌患者的疗效关系。方法：纳入我院2013年1月至2014年11月确诊为EGFR突变型晚期非小细胞肺癌的患者50例，口服吉非替尼进行治疗，直至疾病进展或者出现不可耐受的毒副反应，采用免疫组织化学方法、RT-PCR检测EGFR突变型晚期非小细胞肺癌患者中BRCA1的表达情况，并通过收集的临床资料回顾性分析吉非替尼对EGFR突变型晚期非小细胞肺癌病人的治疗效果。结果：不同预后的EGFR突变型晚期非小细胞肺癌患者，BRCA1阳性细胞表达及BRCA1mRNA表达水平随着预后的不良而增加，平均表达水平的组间差异有统计学意义；BRCA1高表达率为36.00%（18/50），BRCA1高表达组吉非替尼有效率为33.33%（6/18），BRCA1低表达组吉非替尼有效率为68.75%（22/32），两者差异有统计学意义（P＜0.05）。结论：吉非替尼治疗EGFR突变型晚期非小细胞肺癌患者中，BRCA1低表达患者受益比高表达患者明显，BRCA1可以作为吉非替尼治疗EGFR突变型晚期非小细胞肺癌的预测因素。 关键词：BRCA1；EGFR突变型晚期非小细胞肺癌；吉非替尼；疗效关系 The relationship between the BRCA1 expression and the efficacy of gefitinib in advanced non-small cell lung cancer patients with EGFR mutation Zhangshunda Fengweineng Xianhaibing Wujing Tangyicong Chenzecheng Dengyanming Foshan city first peoples hospital（Foshan hospital affiliated to sun yat-sen university） 528000 Abstract: Objective: To investigate the relationship between the BRCA1 expression and the efficacy of gefitinib in advanced non-small cell lung cancer(NSCLC) patients with EGFR mutation. Methods: 50 advanced NSCLC patients with EGFR mutation were received oral gefitinib treatment until disease progression or intolerable toxicity occurs in our hospital from January 2013 to November 2014. The expressions of BRCA1 in these patients were detected by immunohistochemistry. And the therapeutic effect of gefitinib for advanced NSCLC patients with EGFR mutation were analyzed by collecting the clinical datas retrospectively. Results: BRCA1 expression rate was 36.00% (18/50).The response rate was 33.33% (6/18) in high BRCA1 expression group and was 68.75% (22/32) in low BRCA1 expression group, and the difference was statistically significant (P 0.05). Conclusion: In the treatment of Gefitinib for advanced NSCLC patients with EGFR mutation, patients with low BRCA1 expression wer